Home › Funds › TCG Crossover Management, LLC › OCUL
TCG Crossover Management, LLC position in OCUL
OCULAR THERAPEUTIX INC · Health Care
TCG Crossover Management, LLC reported holding 1,647,752 shares of OCUL (OCULAR THERAPEUTIX INC) in its Q2 2026 13F filing — a position valued at US$16.2M, representing 0.39% of its reported portfolio and ranking #43 among its reported holdings. TCG Crossover Management, LLC has disclosed OCUL holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How TCG Crossover Management, LLC's OCUL position evolved
TCG Crossover Management, LLC first disclosed a stake in OCUL in Q1 2024 at 5,319,148 shares (US$48.4M). The position peaked in Q3 2025 at 6,117,232 shares, worth US$71.5M. Across 10 filings, TCG Crossover Management, LLC increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 6 time(s). The most recent filing (Q2 2026) shows 1,647,752 shares valued at US$16.2M. Notable position changes include a 71% trim in Q1 2026 (shares rose 16% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 5.32M | $48.40M | New |
| Q2 2024 | 5.32M | $36.38M | Hold |
| Q3 2024 | 5.32M | $46.28M | Hold |
| Q4 2024 | 5.32M | $45.43M | Hold |
| Q1 2025 | 5.32M | $38.99M | Hold |
| Q2 2025 | 5.32M | $49.36M | Hold |
| Q3 2025 | 6.12M | $71.51M | Add |
| Q4 2025 | 5.74M | $69.69M | Reduce |
| Q1 2026 | 1.65M | $13.96M | Reduce |
| Q2 2026 | 1.65M | $16.18M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About OCUL and 13F data
OCUL (OCULAR THERAPEUTIX INC) is a Health Care company. 42 other funds we track also report a position in OCUL — the largest reported positions include Deep Track Capital, LP (US$193.3M), Avoro Capital Advisors LLC (US$123.1M), SUMMER ROAD LLC (US$119.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding OCUL
- Deep Track Capital, LP 19.69M sh · $193.32M · Q2 2026
- Avoro Capital Advisors LLC 12.54M sh · $123.14M · Q2 2026
- SUMMER ROAD LLC 12.21M sh · $119.89M · Q2 2026
- Venrock Adviser, LLC 10.35M sh · $101.61M · Q2 2026
- Logos Global Management LP 5.30M sh · $52.05M · Q2 2026
- DELTEC ASSET MANAGEMENT LLC 2.48M sh · $24.32M · Q2 2026
- Octagon Capital Advisors LP 2.08M sh · $20.38M · Q2 2026
- Defilade Capital Management, L.P. 1.49M sh · $14.63M · Q2 2026
- Boxer Capital Management, LLC 1.30M sh · $12.77M · Q2 2026
- Knoll Capital Management, LLC 1.15M sh · $11.30M · Q2 2026
More on TCG Crossover Management, LLC
FAQ
How long has TCG Crossover Management, LLC held OCUL?
TCG Crossover Management, LLC has disclosed OCUL holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
What is TCG Crossover Management, LLC's current position in OCUL?
As of Q2 2026, TCG Crossover Management, LLC holds 1.65M shares of OCUL (OCULAR THERAPEUTIX INC), valued at $16.18M, representing 0.39% of its reported portfolio and ranking #43.
Has TCG Crossover Management, LLC been buying or selling OCUL?
In the latest 13F filing (Q2 2026), TCG Crossover Management, LLC held unchanged its position in OCUL. The position peaked in Q3 2025 at 6.12M shares.
Which other funds hold OCUL?
Other major institutional holders of OCUL include Deep Track Capital, LP, Avoro Capital Advisors LLC, SUMMER ROAD LLC, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.